White Matter Lesions Detected by Magnetic Resonance Imaging After Radiotherapy and High-Dose Chemotherapy in Children With Medulloblastoma or Primitive Neuroectodermal Tumor
White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI)...
Saved in:
Published in | Journal of clinical oncology Vol. 22; no. 22; pp. 4551 - 4560 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Baltimore, MD
American Society of Clinical Oncology
15.11.2004
Lippincott Williams & Wilkins |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings.
Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had > or = 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement.
Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% +/- 3%. Patients with WMLs had a significant decline in estimated IQ (-2.5 per year; P = .03) and math (-4.5 per year; P = .003) scores.
WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline. |
---|---|
AbstractList | White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings.
Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had > or = 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement.
Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% +/- 3%. Patients with WMLs had a significant decline in estimated IQ (-2.5 per year; P = .03) and math (-4.5 per year; P = .003) scores.
WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline. Purpose White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings. Patients and Methods Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had ≥ 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement. Results Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% ± 3%. Patients with WMLs had a significant decline in estimated IQ (−2.5 per year; P = .03) and math (−4.5 per year; P = .003) scores. Conclusion WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline. |
Author | Maryam Fouladi Charles W. McCluggage Murali Chintagumpala David Ashley Stewart J. Kellie Amar Gajjar Mehmet Kocak Kevin Krull Fred H. Laningham Shaio Woo Larry E. Kun Raymond K. Mulhern James W. Langston |
Author_xml | – sequence: 1 givenname: Maryam surname: FOULADI fullname: FOULADI, Maryam organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 2 givenname: Murali surname: CHINTAGUMPALA fullname: CHINTAGUMPALA, Murali organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 3 givenname: Larry E surname: KUN fullname: KUN, Larry E organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 4 givenname: Raymond K surname: MULHERN fullname: MULHERN, Raymond K organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 5 givenname: Amar surname: GAJJAR fullname: GAJJAR, Amar organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 6 givenname: Fred H surname: LANINGHAM fullname: LANINGHAM, Fred H organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 7 givenname: David surname: ASHLEY fullname: ASHLEY, David organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 8 givenname: Stewart J surname: KELLIE fullname: KELLIE, Stewart J organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 9 givenname: James W surname: LANGSTON fullname: LANGSTON, James W organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 10 givenname: Charles W surname: MCCLUGGAGE fullname: MCCLUGGAGE, Charles W organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 11 givenname: Shaio surname: WOO fullname: WOO, Shaio organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 12 givenname: Mehmet surname: KOCAK fullname: KOCAK, Mehmet organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia – sequence: 13 givenname: Kevin surname: KRULL fullname: KRULL, Kevin organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16283598$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15542806$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkUFrGzEQhUVJaZy0596KLqWndaTVaiUfg9MmKU5TQkp6E1rtyKuwKxlJbvCP6n-sjE0DgkHMe4-Zb87QiQ8eEPpIyZzWhFx8X97PS23mhM0Jl2_QjPJaVEJwfoJmRLC6opL9PkVnKT0TQhvJ-Dt0SjlvaknaGfr7NLgM-E7nDBGvILngE76CDCZDj7tdaa09ZGfwA6TgtTeAbye9dn6NL-3e9KB7F_IAUW92WPse37j1UF2FBHg5wPS_5Xz5u7GP4PGTywO-g347jqEbdcph0jhE_DO6yWX3B_AP2MZQhgg9xEmP-HE7hfgevbV6TPDhWM_Rr29fH5c31er--nZ5uaoM4yJXhnO96IFq2WopiGGia5pWiNqA5aRtbEeopa2UYBhpLKFCMrowmtiuI8QCO0cXh1wTQ0oRrNqUwXTcKUrUHrwq4NUevCJMFfDF8eng2Gy7CfpX_ZF0EXw-CnQyerSxkHTpVdfW5TSLfdCXg24oFF9cBJXK-mOJrdWzCXWtyms4p-wfz_ud2g |
CitedBy_id | crossref_primary_10_1002_pbc_24954 crossref_primary_10_1016_j_ijrobp_2007_07_2377 crossref_primary_10_1016_j_ijrobp_2015_05_018 crossref_primary_10_1002_cncr_22129 crossref_primary_10_1002_pbc_26619 crossref_primary_10_21682_2311_1267_2020_7_2_126_33 crossref_primary_10_1002_cncr_22761 crossref_primary_10_1016_S1470_2045_17_30030_X crossref_primary_10_1016_j_ijrobp_2019_08_039 crossref_primary_10_1586_14737140_6_5_709 crossref_primary_10_1093_neuonc_noad186 crossref_primary_10_3389_fncel_2019_00241 crossref_primary_10_1016_j_ijrobp_2014_08_354 crossref_primary_10_1007_s11060_021_03799_3 crossref_primary_10_1016_j_ijrobp_2006_12_030 crossref_primary_10_1016_j_neuropsychologia_2008_08_011 crossref_primary_10_3174_ajnr_A7393 crossref_primary_10_3390_cancers16091716 crossref_primary_10_1007_s00280_016_3161_0 crossref_primary_10_1002_jmri_21364 crossref_primary_10_1200_JCO_2008_18_6437 crossref_primary_10_3389_fonc_2022_874317 crossref_primary_10_1016_j_radonc_2019_05_020 crossref_primary_10_1016_S2173_5107_11_70007_6 crossref_primary_10_1111_ped_14409 crossref_primary_10_1016_j_ijrobp_2011_02_059 crossref_primary_10_1007_s12264_023_01096_9 crossref_primary_10_14338_IJPT_15_00036_1 crossref_primary_10_1111_j_1440_1789_2008_00945_x crossref_primary_10_1007_s11060_011_0794_z crossref_primary_10_1007_s00280_008_0859_7 crossref_primary_10_1016_j_jns_2009_06_031 crossref_primary_10_1634_theoncologist_2008_0130 crossref_primary_10_1007_s11060_018_03063_1 crossref_primary_10_1016_j_ijrobp_2017_11_026 crossref_primary_10_1016_j_path_2020_01_004 crossref_primary_10_1007_s00066_013_0408_0 crossref_primary_10_1080_09297049_2023_2172149 crossref_primary_10_1016_j_ijrobp_2007_01_034 crossref_primary_10_1016_j_ijrobp_2015_09_015 crossref_primary_10_1007_s11060_015_1962_3 crossref_primary_10_18632_oncotarget_19553 crossref_primary_10_1002_pbc_25901 crossref_primary_10_1177_2096595820902565 crossref_primary_10_1002_pbc_25946 crossref_primary_10_1080_13854046_2020_1794045 crossref_primary_10_1007_s00401_005_0023_y crossref_primary_10_1093_nop_npaa002 crossref_primary_10_3389_fonc_2021_573798 crossref_primary_10_1080_13854046_2016_1216070 crossref_primary_10_3171_jns_2005_102_2_0179 crossref_primary_10_1016_j_neuchi_2018_03_002 crossref_primary_10_1080_14737175_2017_1375405 crossref_primary_10_1080_09297049_2021_1885639 crossref_primary_10_1016_j_ijrobp_2008_03_056 crossref_primary_10_1016_j_nicl_2021_102891 crossref_primary_10_1016_S1470_2045_06_70867_1 crossref_primary_10_1080_09553002_2017_1387305 crossref_primary_10_3390_cancers14030837 crossref_primary_10_1634_stemcells_2007_1009 crossref_primary_10_1016_j_ijrobp_2017_11_037 crossref_primary_10_1093_neuonc_nos212 crossref_primary_10_1007_s12253_011_9464_x crossref_primary_10_1007_s12311_020_01225_4 crossref_primary_10_1016_j_neurad_2022_03_007 crossref_primary_10_1080_14737175_2018_1425617 crossref_primary_10_1093_neuonc_noab301 crossref_primary_10_1016_j_radonc_2016_11_001 crossref_primary_10_1016_S1470_2045_05_70252_7 crossref_primary_10_1186_1748_717X_5_9 crossref_primary_10_3390_bioengineering5030073 crossref_primary_10_1097_RCT_0000000000001481 crossref_primary_10_1016_j_ejpn_2015_07_011 crossref_primary_10_1016_j_neuchi_2008_07_012 crossref_primary_10_1111_1754_9485_12232 crossref_primary_10_3174_ajnr_A3219 crossref_primary_10_1016_j_ijrobp_2019_06_2534 crossref_primary_10_1044_2018_PERS_SIG2_2018_0021 crossref_primary_10_3389_fnimg_2022_845609 crossref_primary_10_1093_neuonc_noac044 crossref_primary_10_1093_neuonc_nor015 crossref_primary_10_1016_j_radonc_2024_110157 crossref_primary_10_1007_s11060_008_9726_y crossref_primary_10_3390_cancers14235863 crossref_primary_10_26599_BSA_2019_9050008 crossref_primary_10_3389_fpsyg_2018_00703 crossref_primary_10_1016_S1470_2045_06_70872_5 crossref_primary_10_1016_j_rx_2010_11_005 crossref_primary_10_1016_j_ijrobp_2018_01_013 crossref_primary_10_3109_0284186X_2014_957414 crossref_primary_10_1186_s40348_018_0087_0 crossref_primary_10_1002_pbc_20731 crossref_primary_10_1037_0894_4105_20_1_105 crossref_primary_10_1007_s00247_016_3750_4 crossref_primary_10_1016_S1470_2045_08_70125_6 |
Cites_doi | 10.1093/brain/123.5.1041 10.1212/WNL.35.8.1152 10.1177/155005948201300310 10.1037/0735-7044.108.5.848 10.1212/WNL.51.2.433 10.1111/j.1749-6632.2002.tb07578.x 10.1002/(SICI)1096-911X(199706)28:6<387::AID-MPO1>3.0.CO;2-C 10.1002/1097-0142(19951115)76:10<1846::AID-CNCR2820761025>3.0.CO;2-8 10.1007/s00381-001-0526-3 10.1016/S0360-3016(99)00367-3 10.1002/1097-0142(19940915)74:6<1827::AID-CNCR2820740628>3.0.CO;2-Q 10.1212/WNL.59.1.40 10.1002/1097-0142(19921001)70:7<1997::AID-CNCR2820700732>3.0.CO;2-G 10.1002/cncr.11355 10.1016/S0360-3016(99)00366-1 10.1016/0028-3932(96)00001-2 10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M 10.1227/00006123-199110000-00025 10.1200/JCO.1992.10.2.249 10.1016/0028-3932(92)90105-U 10.1002/1097-0142(19851115)56:10<2430::AID-CNCR2820561017>3.0.CO;2-3 10.1016/S0730-725X(00)00182-X 10.1093/brain/121.11.2175 10.1002/1097-0142(19860801)58:3<635::AID-CNCR2820580307>3.0.CO;2-X 10.1016/S0360-3016(98)00514-8 10.1016/0360-3016(94)00655-5 10.1016/S0730-725X(98)00014-9 10.1200/JCO.2001.19.8.2302 10.1002/1097-0142(19921201)70:11<2728::AID-CNCR2820701126>3.0.CO;2-7 10.1001/archneur.1996.00550080140022 10.1002/mpo.2950130607 10.1212/WNL.43.8.1536 10.1093/brain/121.4.561 10.1016/S0360-3016(00)00471-5 10.1002/mpo.2950220216 10.1056/NEJM197804132981504 |
ContentType | Journal Article |
Copyright | 2005 INIST-CNRS |
Copyright_xml | – notice: 2005 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1200/JCO.2004.03.058 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 4560 |
ExternalDocumentID | 10_1200_JCO_2004_03_058 15542806 16283598 jco22_22_4551 |
Genre | Multicenter Study Research Support, U.S. Gov't, P.H.S Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA21765 |
GroupedDBID | - 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 8WZ A6W AAPEM AARDX AAWTL AAYEP ABFLS ABOCM ACDCL ACGFS ADBBV ADBIT ADKWQ AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AWKKM AZFZN BAWUL CS3 DIK EBS EJD F5P FD8 FH7 GJ GX1 H13 HZ IH2 K-O KQ8 L7B LSO N9A NTWIH O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 X7M YCJ ZA5 ZGI --- .55 .GJ 08G 08P 08R 0R~ 18M 29K 5VS AAKAS AAQQT AAUGY AAYOK ACGFO ADZCM AEGXH AI. AIAGR C45 D-I EX3 F9R FBNNL FEDTE HZ~ IPNFZ IQODW J5H MJL N4W QTD R1G RIG RLZ TEORI TR2 UHU VVN WOQ WOW YFH YQY ABJNI ACGUR CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c357t-c55a9de1a86a870c37b446772cef5064fb01f1688ec304f0178319ca0fbb00fe3 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 03:02:05 EDT 2024 Sat Sep 28 07:44:01 EDT 2024 Sun Oct 22 16:07:56 EDT 2023 Tue Jan 05 20:16:52 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Keywords | Human Antineoplastic agent Radiotherapy Nuclear magnetic resonance imaging White matter Neuroectodermal tumor Chemotherapy Primitive Cancerology Treatment Medulloblastoma Medical imagery Lesion High dose Child |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c357t-c55a9de1a86a870c37b446772cef5064fb01f1688ec304f0178319ca0fbb00fe3 |
PMID | 15542806 |
PageCount | 10 |
ParticipantIDs | crossref_primary_10_1200_JCO_2004_03_058 pubmed_primary_15542806 pascalfrancis_primary_16283598 highwire_smallpub2_jco22_22_4551 |
ProviderPackageCode | RHI |
PublicationCentury | 2000 |
PublicationDate | 2004-11-15 |
PublicationDateYYYYMMDD | 2004-11-15 |
PublicationDate_xml | – month: 11 year: 2004 text: 2004-11-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Baltimore, MD |
PublicationPlace_xml | – name: Baltimore, MD – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2004 |
Publisher | American Society of Clinical Oncology Lippincott Williams & Wilkins |
Publisher_xml | – name: American Society of Clinical Oncology – name: Lippincott Williams & Wilkins |
References | R41 R40 R21 R20 R42 R23 R22 R25 R24 R27 R26 R29 R28 R1 R2 R3 R4 R5 R6 R7 R8 R9 R30 R10 R32 R31 R12 R34 R11 R33 R14 R36 R13 R35 R16 R38 R15 R37 R18 R17 R39 R19 |
References_xml | – ident: R36 doi: 10.1093/brain/123.5.1041 – ident: R35 doi: 10.1212/WNL.35.8.1152 – ident: R21 doi: 10.1177/155005948201300310 – ident: R34 doi: 10.1037/0735-7044.108.5.848 – ident: R38 doi: 10.1212/WNL.51.2.433 – ident: R42 doi: 10.1111/j.1749-6632.2002.tb07578.x – ident: R3 doi: 10.1002/(SICI)1096-911X(199706)28:6<387::AID-MPO1>3.0.CO;2-C – ident: R2 doi: 10.1002/1097-0142(19951115)76:10<1846::AID-CNCR2820761025>3.0.CO;2-8 – ident: R8 doi: 10.1007/s00381-001-0526-3 – ident: R30 doi: 10.1016/S0360-3016(99)00367-3 – ident: R18 doi: 10.1002/1097-0142(19940915)74:6<1827::AID-CNCR2820740628>3.0.CO;2-Q – ident: R19 doi: 10.1212/WNL.59.1.40 – ident: R1 doi: 10.1002/1097-0142(19921001)70:7<1997::AID-CNCR2820700732>3.0.CO;2-G – ident: R28 doi: 10.1002/cncr.11355 – ident: R29 doi: 10.1016/S0360-3016(99)00366-1 – ident: R32 doi: 10.1016/0028-3932(96)00001-2 – ident: R26 doi: 10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M – ident: R22 doi: 10.1227/00006123-199110000-00025 – ident: R24 doi: 10.1200/JCO.1992.10.2.249 – ident: R33 doi: 10.1016/0028-3932(92)90105-U – ident: R31 – ident: R14 – ident: R37 – ident: R6 doi: 10.1002/1097-0142(19851115)56:10<2430::AID-CNCR2820561017>3.0.CO;2-3 – ident: R27 doi: 10.1016/S0730-725X(00)00182-X – ident: R39 doi: 10.1093/brain/121.11.2175 – ident: R10 doi: 10.1002/1097-0142(19860801)58:3<635::AID-CNCR2820580307>3.0.CO;2-X – ident: R12 doi: 10.1016/S0360-3016(98)00514-8 – ident: R13 doi: 10.1016/0360-3016(94)00655-5 – ident: R25 doi: 10.1016/S0730-725X(98)00014-9 – ident: R16 doi: 10.1200/JCO.2001.19.8.2302 – ident: R5 doi: 10.1002/1097-0142(19921201)70:11<2728::AID-CNCR2820701126>3.0.CO;2-7 – ident: R9 doi: 10.1001/archneur.1996.00550080140022 – ident: R7 doi: 10.1002/mpo.2950130607 – ident: R40 doi: 10.1212/WNL.43.8.1536 – ident: R41 doi: 10.1093/brain/121.4.561 – ident: R11 – ident: R20 doi: 10.1016/S0360-3016(00)00471-5 – ident: R23 doi: 10.1002/mpo.2950220216 – ident: R4 doi: 10.1056/NEJM197804132981504 – ident: R15 – ident: R17 |
SSID | ssj0014835 |
Score | 2.2143626 |
Snippet | White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect... Purpose White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute... |
SourceID | crossref pubmed pascalfrancis highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 4551 |
SubjectTerms | Adolescent Atrophy Biological and medical sciences Brain - pathology Brain Neoplasms - radiotherapy Case-Control Studies Cerebellar Neoplasms - radiotherapy Child Cognition Disorders - etiology Cranial Irradiation - adverse effects Female Humans Incidence Magnetic Resonance Imaging Male Medical sciences Medulloblastoma Necrosis Neuroectodermal Tumors, Primitive - radiotherapy Neurology Prospective Studies Radiation Injuries - epidemiology Radiation Injuries - pathology Radiotherapy, Conformal Risk Factors Tumors Tumors of the nervous system. Phacomatoses |
Title | White Matter Lesions Detected by Magnetic Resonance Imaging After Radiotherapy and High-Dose Chemotherapy in Children With Medulloblastoma or Primitive Neuroectodermal Tumor |
URI | http://jco.ascopubs.org/content/22/22/4551.abstract https://www.ncbi.nlm.nih.gov/pubmed/15542806 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELa2ISG-IBgDyst0H9CE1HWkzkvTj1PHKGihE-pEv0WOk2xFbTK1KVL5T_xH7uw4SQuIF6mK2lRynd49d2f77jnGXkVp4kcJRm5OatsdpysRUlY_xkBOeFI4GJMK2tAPPnrDK-fDxJ3s7B40spZWRXQiv_2yruR_pIr3UK5UJfsPkq0GxRv4HuWLV5QwXv9Kxqq7XTtQFJnti2SpktrOEjoX0IFlIK4zqlJUu_SZqg54P9d9iU5Vc_BPIp6WNViaiInyPjpnlMROVALVV1QbaMq-P9PWbYAuajbLIwy-i3wuKK39kjqEqUwkxfhBxwEx2f1Ze7ya54vfhMFVaWaeyY0t_kAs1mJOfZ9mOMmGYuDKQbX9LsQ16qKYVY7lnHLphyftC0GbPTdiXm_Df53GqIk35hTbbHM4VO-nCz0blQVk8spkVkpWMRMcNSeobWfP5h20VhPt5krbznuog5oV2Bh_zhtKXn7QptxxNRPuTz6G6_bZg5HaXVAUuZp9vqFxt3OlchSs0dF17WxNgsGWD64yI7_InPMQX_Tzu-wOR_tJhvvdpMpcwgWs7htrnrFkrMLZvNmalWo6paewGXcZLmxKBRZL_A9T3cZla3GlgqzxA3a_VAs41ar-kO0k2T67G5T5H_vs6FIzra-PYVwXDi6P4Qguaw729SP2XUEDNDSghAYYaEC0BgMNqKABJTRAQQOa0ACEBlTQgCY0YJqBgQYQNGALGpAvoIIGbEEDFDQO2NX52_Fg2Ck7k3Sk7faKjnRd0Y-TrvA9gQ5P2r3IwYijx2WSEgNkGlndtOv5fiJty0nR6_no6qSw0gjdXJrYj9lelmfJUwZp6nuelE7sxrYjXS6k3-eWiPsyjuzIky322sgtvNUENCEt3DmdQg9G1EbWCS07RGm3GBi5hkt8hBmKkocbGtVihxvyrof0iHixj2M80QpQf1Mq0LM_j_6c3auh-4LtFYtV8hJj9iI6VBr8A9VO9Bk |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=White+Matter+Lesions+Detected+by+Magnetic+Resonance+Imaging+After+Radiotherapy+and+High-Dose+Chemotherapy+in+Children+With+Medulloblastoma+or+Primitive+Neuroectodermal+Tumor&rft.jtitle=Journal+of+clinical+oncology&rft.au=Maryam+Fouladi&rft.au=Murali+Chintagumpala&rft.au=Fred+H.+Laningham&rft.au=David+Ashley&rft.date=2004-11-15&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=22&rft.issue=22&rft.spage=4551&rft_id=info:doi/10.1200%2FJCO.2004.03.058&rft_id=info%3Apmid%2F15542806&rft.externalDBID=n%2Fa&rft.externalDocID=jco22_22_4551 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |